Aclaris Therapeutics Inc

ACRS

Add to Watchlist

4.520USD

-0.280-5.83%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Aclaris Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

92 / 382

Overall Ranking

212 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Aclaris Therapeutics Inc Highlights

StrengthsRisks

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.83M.

Undervalued

The company’s latest PE is -8.07, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 101.56M shares, increasing 0.01% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 168.58K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

9.450

Target Price

+96.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Aclaris Therapeutics Inc is 5.52, ranking 341 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 2.00M, representing a year-over-year increase of 37.18%, while its net profit experienced a year-over-year increase of 31.42%.

Score

Industry at a Glance

Previous score

5.52

Change

0



Financials

5.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.95

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Aclaris Therapeutics Inc is 7.13, ranking 158 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.07, which is -95.21% below the recent high of -0.39 and -66.98% above the recent low of -13.47.

Score

Industry at a Glance

Previous score

7.13

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 92/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Aclaris Therapeutics Inc is 8.67, ranking 70 out of 382 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 16.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.91

Change

-0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Aclaris Therapeutics Inc is 6.79, ranking 151 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.09 and the support level at 4.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.46

Change

-1.67

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Aclaris Therapeutics Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 72.75%, representing a quarter-over-quarter decrease of 32.53%. The largest institutional shareholder is James Simons, holding a total of 502.63K shares, representing 0.36% of shares outstanding, with 59.04% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BML Capital Management LLC

14.25M

--

Deep Track Capital LP

9.35M

--

Vivo Capital, LLC

8.89M

--

BlackRock Institutional Trust Company, N.A.

6.12M

+19.22%

Rock Springs Capital Management LP

4.45M

-3.38%

Decheng Capital LLC

4.04M

--

Adage Capital Management, L.P.

3.37M

-36.13%

Geode Capital Management, L.L.C.

2.39M

+0.14%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aclaris Therapeutics Inc is 3.45, ranking 134 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Aclaris Therapeutics Inc

ACRS

6.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment